PD-1 antibodies (i.e., pembrolizumab and nivolumab) and PD-L1 antibodies (i.e., atezolizumab, durvalumab, and avelumab) have generated effective efficacy in multiple kinds of malignancies [8,9,10,11,18]. The gene discussed is CD274; the disease is cancer.